DEA Delays in Scheduling Are Offsetting FDA’s Improved Decision Making
This article was originally published in RPM Report
FDA is showing a renewed commitment to meeting review deadlines for new molecular entities, but that is not translating into earlier commercial availability for all NMEs. Some products also need a controlled substance scheduling decision from the Drug Enforcement Administration; those actions have become a new regulatory purgatory that can be painful and frustrating.
You may also be interested in...
Merck Suvorexant Scheduled, But DEA Delays Remain an Issue
DEA scheduled Merck’s Belsomra (suvorexant) August 28, only two weeks after its August 13 approval – much faster than the year-long wait for some drugs. But don’t take that to mean that the DEA process is moving faster for new drugs.
Sunovion Sees Advantage For Aptiom As Unscheduled Epilepsy Drug
Dainippon subsidiary plans to launch its next-generation version of carbamazepine in the second half of 2014. Lack of classification as a controlled substance means more direct access to prescribers, company says.
NCE Market Exclusivity: Eisai Targets DEA Scheduling Delays, Pozen Pushes Bill For Combo Products
Eisai citizen petition requests Belviq and Fycompa approval dates coincide with final DEA scheduling; Pozen advocates exclusivity for new combinations of previously approved molecules.